Omentin-1 levels in patients with premature coronary artery disease, metabolic syndrome and healthy controls. Short communication

• Main Authors: David Stejskal, Jan Vaclavik, Ales Smekal, Gabriela Svobodova, Radmila Richterova, Marek Svestak
• Format: Article
• Language: English
• Published: Palacký University Olomouc, Faculty of Medicine and Dentistry 2016-06-01
• Series: Biomedical Papers
• Subjects: omentin-1; acute myocardial infarction; coronary artery disease; premature manifestation; adipokines; elisa
• Online Access: https://biomed.papers.upol.cz/artkey/bio-201602-0006_Omentin-1_levels_in_patients_with_premature_coronary_artery_disease_metabolic_syndrome_and_healthy_controls_S.php

Objectives: Omentin-1 is an adipokine which could have a protective role against the manifestation of atherosclerosis. Only limited data are available on omentin-1 serum values in patients with premature clinical manifestations of atherosclerosis. Design and Methods. We tested omentin-1 in human serum by ELISA method in 61 individuals with a premature manifestation of coronary artery disease (CAD), 40 patients with metabolic syndrome and 40 healthy control subjects. Results: Omentin-1 serum levels were significantly lower in patients with CAD (103.1±62.7 mg/L) compared to metabolic syndrome (668.2±339.6 mg/L) and healthy subjects (623.0±373.5 mg/L) (P < 0.01). In CAD patients, omentin-1 serum levels did not differ between patients sampled in the acute phase of myocardial infarction (n = 28; 110.3±82.4 mg/L) and in the chronic phase several months or years after myocardial infarction (n = 33; 97.0±39.3 mg/L) (P = 0.41). We found a weak positive correlation between omentin-1 and body mass index (r = 0.21, P = 0.014). No significant correlation was found between peak cardiac troponin T and omentin-1 (correlation coefficient r = 0.118, P = 0.406). Conclusion: Serum omentin-1 seems to be a useful biomarker of coronary artery disease across the whole age spectrum.